Thank you authors and the faculty and residents from UChicago for a great discussion so far! Earlier in the discussion it was mentioned that with the number of drugs available out there, it's challenging to study all the different combinations. In the oncology-sphere, there is a similar challenge, and trialists have adopted multi-arm designs that adapt at interim analyses with selective dropping out of arms due to futility or efficacy. Cardiology has so far done well with classic trial designs and stuck to them. What do the authors see as barriers and differences between the fields for not using more sophisticated trial designs to do more with fewer patients?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.